Table 3 Cox proportional hazards regression for recurrence-free survival (n = 430) with competing risks

Age

0.98 (0.96–0.99)

0.020

0.98 (0.98–1.00)

0.045

Gender

Male

1.36 (0.86–2.14)

0.190

1.62 (0.99–2.66)

0.057

Female

Ref

ASA

≥ 3

0.81 (0.57–1.15)

0.232

0.91 (0.62–1.33)

0.620

≤ 2

Ref

Anesthesia

GA + Epidural

1.43 (1.00–2.04)

0.048

1.67 (1.14–2.45)

0.009

GA

Ref

pN stage

N+

1.76 (1.21–2.55)

0.003

1.24 (0.82–1.88)

0.308

N0/Nx

Ref

pT stage

≥ T3

2.47 (1.74–3.52)

< 0.001

2.22 (1.43–3.46)

0.0004

≤ T2

Ref

Margin (radial/ureteral/urethral)

Positive

1.42 (0.95–2.12)

0.091

1.23 (0.78–1.94)

0.370

Negative

Ref

Neoadjuvant chemotherapy

Yes

1.69 (1.18–2.43)

0.005

1.66 (1.14–2.43)

0.009

No

Ref

Adjuvant chemotherapy

Yes

2.17 (1.49–3.16)

< 0.001

1.34 (0.85–2.11)

0.206

No

Ref